Ambarella Inc vs ResMed Inc. — how do they compare? Ambarella Inc trades at $82.73 (market cap $3.60B), while ResMed Inc. trades at $222.39 (market cap $31.92B). The key difference: ResMed Inc. is far larger — about 8.9× Ambarella Inc's market cap, and ResMed Inc. pays a 1.2% dividend while Ambarella Inc pays none. Which is the better fit depends on your goals.
| AMBA | RMD | |
|---|---|---|
Market Cap | $3.60B | $31.92B |
Sector | Technology | Health |
52-Week High | $95.51 | $293.73 |
52-Week Low | $48.65 | $182.82 |
Enterprise Value | $3.33B | $31.28B |
Dividend Yield | — | 1.2% |
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $86.78, up 3.57% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics. Recent news highlights NXP's potential acquisition interest and the company's strategic pivot to edge AI chips, driving analyst optimism. Q2 2026 earnings are expected at $0.171 per share, following three consecutive quarterly beats. Revenue growth is projected to accelerate from $285M in 2025 to $405M in 2026.
Outlook remains positive with 58% analyst buy ratings and $108.67 price target, but risks include persistent net losses, high valuation multiples, and competitive pressure in semiconductor space. The edge AI transition offers growth potential, yet execution risks and insider selling warrant caution for investors.
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
Trailing returns across standard periods
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →